- Trials with a EudraCT protocol (74)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
74 result(s) found for: Tuberculin.
Displaying page 1 of 4.
EudraCT Number: 2007-003420-38 | Sponsor Protocol Number: PPD1 | Start Date*: 2007-12-28 | ||||||||||||||||
Sponsor Name:Umeå University | ||||||||||||||||||
Full Title: The effect of Rapydan lidocain/tetracain patch on pain-response and reproducibilty in Tuberculin test | ||||||||||||||||||
Medical condition: Pain response to intradermal injection of tuberculin. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005617-36 | Sponsor Protocol Number: TESEC-06 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: A phase III contact tracing trial comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomized split body safety assessment of C-Tb ve... | |||||||||||||
Medical condition: Tuberculosis diagnostic tool | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005664-88 | Sponsor Protocol Number: HB996 | Start Date*: 2006-12-08 |
Sponsor Name:University of Oxford | ||
Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ... | ||
Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017296-17 | Sponsor Protocol Number: TESEC-03 | Start Date*: 2011-04-04 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: A phase IIa specificity trial of the diagnostic agent C-Tb, when given intradermally by the Mantoux technique to healthy volunteers previously vaccinated with BCG | |||||||||||||
Medical condition: The intended indication for the product is to be a diagnostic tool to detect infection with M.tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004110-32 | Sponsor Protocol Number: D1521C00002 | Start Date*: 2005-12-01 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients wit... | ||
Medical condition: Chronic Obstructive Pulmonary Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) HU (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005645-20 | Sponsor Protocol Number: A3921082 | Start Date*: 2013-06-25 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A PHASE 2B, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY, SAFETY, LOCAL TOLERABILITY AND PHARMACOKINETICS OF 2 DOSE STRENGTHS AND 2 REGIMENS OF TOF... | |||||||||||||
Medical condition: Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003530-17 | Sponsor Protocol Number: C0743T09 | Start Date*: 2006-07-21 |
Sponsor Name:Centocor B.V. | ||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis | ||
Medical condition: Moderate to severe plaque psoriasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004067-30 | Sponsor Protocol Number: CO168X94 (EU-116) | Start Date*: 2006-05-08 |
Sponsor Name:Department of Rheumatology, Internal Medicine III, Medical University of Vienna | ||
Full Title: A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Ery... | ||
Medical condition: Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-001742-16 | Sponsor Protocol Number: C0524T11 | Start Date*: 2006-05-26 |
Sponsor Name:Centocor B.V. | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... | ||
Medical condition: Active rheumatoid arthritis (RA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) NL (Completed) DE (Completed) AT (Completed) FI (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000181-39 | Sponsor Protocol Number: C0168X84, EU-0108 | Start Date*: 2005-08-31 |
Sponsor Name:Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher | ||
Full Title: A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity | ||
Medical condition: Insulin Resistant Human Obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007170-30 | Sponsor Protocol Number: TUD-Psslan-031 | Start Date*: 2008-06-03 |
Sponsor Name:Technical University of Dresden, faculty of medicine | ||
Full Title: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and f... | ||
Medical condition: Psoriasis vulgaris | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2009-013539-39 | Sponsor Protocol Number: 20090062 | Start Date*: 2009-11-24 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis | |||||||||||||
Medical condition: Moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005078-40 | Sponsor Protocol Number: TESEC-05 | Start Date*: 2016-06-03 |
Sponsor Name:Statens Serum Institut | ||
Full Title: A Phase III trial in subjects suspected to have tuberculosis, comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomised splitbody s... | ||
Medical condition: Children (28 days–4 years old) with suspected Mycobacterium tuberculosis infection Participants between 5–65 years old who attended the TB clinic due to suspicion of TB disease (HIV positive and HI... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-001429-32 | Sponsor Protocol Number: CACZ885D2201 | Start Date*: 2012-03-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, open label, 24-month treatment study to establish the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab (anti-IL-1 beta antibody) in patients with... | |||||||||||||
Medical condition: Neonatal onset multisystem inflammatory disease (abbreviated NOMID, also known as chronic infantile neurologic cutaneous and articular syndrome or CINCA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008171-34 | Sponsor Protocol Number: CNTO1275PSO4004 | Start Date*: 2009-09-01 | |||||||||||
Sponsor Name:Janssen-Cilag EMEA Medical Affairs | |||||||||||||
Full Title: AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT) | |||||||||||||
Medical condition: moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) AT (Completed) SE (Completed) BE (Completed) HU (Completed) LT (Completed) DK (Completed) FI (Completed) FR (Completed) SK (Completed) PT (Completed) ES (Completed) GB (Completed) BG (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012566-32 | Sponsor Protocol Number: 20090061 | Start Date*: 2010-02-05 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to... | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LV (Completed) PL (Completed) HU (Completed) BG (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004666-14 | Sponsor Protocol Number: CACZ885A2206 | Start Date*: 2007-06-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003206-58 | Sponsor Protocol Number: CNTO1959PSO3013 | Start Date*: 2019-06-29 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | |||||||||||||
Medical condition: Palmoplantar non-Pustular Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000535-26 | Sponsor Protocol Number: P05133 | Start Date*: 2007-06-04 | |||||||||||
Sponsor Name:SCHERING-PLOUGH | |||||||||||||
Full Title: SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO) | |||||||||||||
Medical condition: Patients with moderate to severe psoriasi. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
